ACH
Accendra Health, Inc.
NYSEUSDEQUITY
Healthcare
DELAYED
Sell
-42/100
Last price
0.47
▲ 0.02 (3.35%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
0.46
Prev close
0.45
Day high
0.50
Day low
0.44
Volume
2.32M
Market cap
$35.85M
P/E (TTM)
—
52W range
0.44 – 5.60
Day trading desk
Gap from prior close
+2.22%
Prior close 0.45
VWAP
0.47
-0.56% from price
Relative volume
4.46×
Unusually busy
Session range
13.44%
0.44 – 0.50
Position in range
40%
Mid range
ATR (14D)
0.07
15.48% of price
Prior day high
0.53
PDH
Prior day low
0.45
PDL
Bid / ask spread
—
Quote not published
Session volume
6.17M
Avg 1.38M
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
-22.95%
-24.9%
1M
-61.16%
-62.3%
3M
-85.17%
-89.7%
6M
-81.50%
-99.7%
YTD
-83.21%
-97.5%
1Y
-90.13%
-106.5%
3Y
-97.09%
-179.3%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on ACH open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
5.91M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| May 14, 26 | KLINE TERESA L. Director |
STOCK | 31.19K | $0 | Direct |
| May 14, 26 | KLEMASH STEPHEN W. Director |
STOCK | 31.19K | $0 | Direct |
| May 14, 26 | GARDNER-SMITH KENNETH Director |
STOCK | 31.19K | $0 | Direct |
| May 14, 26 | BECK MARK A. Director |
STOCK | 31.19K | $0 | Direct |
| Mar 9, 26 | GALLOWAY HEATH H. General Counsel |
STOCK | 61.44K | $0 | Direct |
| Mar 9, 26 | LEON JONATHAN A Chief Financial Officer |
STOCK | 85.07K | $0 | Direct |
| Mar 9, 26 | BERNOCCHI PERRY A Chief Operating Officer |
STOCK | 108.70K | $0 | Direct |
| Nov 19, 25 | LONG ANDREW G. Chief Executive Officer |
STOCK | 47.91K | $0 | Direct |
| Aug 14, 25 | COLISEUM CAPITAL MANAGEMENT, L.L.C. Beneficial Owner of more than 10% of a Class of Security |
BUY | 1.54M | $8.10M | Indirect |
| May 15, 25 | KLINE TERESA L. Director |
STOCK | 28.91K | $0 | Direct |
| May 15, 25 | JOHNSON-MILLS RITA Director |
STOCK | 28.91K | $0 | Direct |
| May 15, 25 | HENKEL ROBERT J Director |
STOCK | 28.91K | $0 | Direct |
| May 15, 25 | KLEMASH STEPHEN W. Director |
STOCK | 28.91K | $0 | Direct |
| May 15, 25 | GARDNER-SMITH KENNETH Director |
STOCK | 28.91K | $0 | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Fundamentals
Market cap$35.85M
Enterprise value$1.85B
Revenue (TTM)$2.65B
Gross profit$1.19B
EBITDA$288.23M
Net income$-110.59M
EPS (TTM)$-1.44
Free cash flow$420.23M
Total cash$7.65M
Total debt$1.82B
Book value / share$-7.16
Shares outstanding76.90M
Float56.52M
Short % of float14.28%
Dividend yield0.00%
Beta (5Y)1.57
Valuation & profitability ratios
Trailing P/E—
Forward P/E5.11
PEG ratio0.70
Price / sales—
Price / book—
EV / revenue0.70
EV / EBITDA6.41
Gross margin44.83%
Operating margin-1.53%
Profit margin-11.41%
Return on equity—
Return on assets0.64%
Debt / equity—
Current ratio0.41
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $2.76B | $2.68B | $2.55B | $9.96B | +3.1% |
| Operating revenue | $2.76B | $2.68B | $2.55B | $9.96B | +3.1% |
| Cost of revenue | $1.47B | $1.40B | $1.34B | $8.13B | +5.2% |
| Gross profit | $1.29B | $1.28B | $1.22B | $1.83B | +0.7% |
| Selling, general & admin | $1.07B | $1.08B | $1.00B | $1.55B | -1.4% |
| Total operating expense | $1.07B | $1.08B | $1.00B | $1.55B | -1.4% |
| Operating income | $221.74M | $198.04M | $215.36M | $276.78M | +12.0% |
| Net interest income | -$107.18M | -$107.57M | -$116.77M | -$128.89M | +0.4% |
| Pre-tax income | -$101.95M | -$329.88M | $15.27M | $10.89M | +69.1% |
| Tax provision | $729.00K | $20.85M | $6.36M | -$11.50M | -96.5% |
| Net income | -$1.10B | -$362.69M | -$41.30M | $22.39M | -203.5% |
| Net income to common | -$1.10B | -$362.69M | -$41.30M | $22.39M | -203.5% |
| Basic EPS | -14.31 | -4.73 | -0.54 | 0.30 | -202.5% |
| Diluted EPS | -14.31 | -4.73 | -0.54 | 0.29 | -202.5% |
| EBIT | $5.23M | -$222.32M | $132.03M | $139.78M | +102.4% |
| EBITDA | $219.75M | -$41.04M | $342.40M | $368.45M | +635.5% |
| Basic shares | 76.90M | 76.74M | 75.78M | 74.50M | +0.2% |
| Diluted shares | 76.90M | 76.74M | 75.78M | 76.22M | +0.2% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $281.99M | $27.57M | $243.04M | $69.47M | +922.7% |
| Cash & short-term investments | $281.99M | $27.57M | $243.04M | $69.47M | +922.7% |
| Accounts receivable | $95.91M | $218.27M | $598.26M | $763.50M | -56.1% |
| Inventory | $74.44M | $67.58M | $1.11B | $1.33B | +10.1% |
| Total current assets | $547.87M | $2.02B | $2.10B | $2.30B | -72.9% |
| Property, plant & equipment | $365.26M | $376.21M | $840.50M | $858.93M | -2.9% |
| Goodwill & intangibles | $1.36B | $1.44B | $2.00B | $2.08B | -5.1% |
| Total assets | $2.45B | $4.66B | $5.09B | $5.39B | -47.3% |
| Total current liabilities | $947.08M | $1.85B | $1.89B | $1.57B | -48.9% |
| Current debt | $250.00M | $42.87M | $206.90M | $17.91M | +483.2% |
| Long-term debt | $1.80B | $1.80B | $1.89B | $2.48B | +0.1% |
| Total debt | $2.12B | $1.93B | $2.32B | $2.72B | +9.8% |
| Total liabilities | $2.91B | $4.07B | $4.17B | $4.44B | -28.4% |
| Retained earnings | -$1.08B | $27.16M | $368.71M | $410.01M | -4,075.7% |
| Shareholder equity | -$460.98M | $586.36M | $924.17M | $945.60M | -178.6% |
| Working capital | -$399.20M | $168.97M | $210.91M | $728.72M | -336.3% |
| Net tangible assets | -$1.83B | -$851.83M | -$1.08B | -$1.14B | -114.3% |
| Shares issued | 76.39M | 77.20M | 76.55M | 76.28M | -1.1% |
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Net income | -$102.68M | -$350.74M | $8.90M | $22.39M | — | +70.7% |
| Depreciation & amortisation | $214.52M | $181.28M | $210.37M | $228.67M | — | +18.3% |
| Stock-based compensation | $12.87M | $16.64M | $14.39M | $20.99M | — | -22.6% |
| Change in working capital | $65.21M | $22.60M | $137.43M | $93.08M | — | +188.5% |
| Operating cash flow | -$101.79M | $161.50M | $740.71M | $325.01M | — | -163.0% |
| Capital expenditure | -$201.32M | -$182.66M | -$178.53M | -$166.58M | — | -10.2% |
| Investing cash flow | $144.42M | -$116.53M | -$137.25M | -$1.80B | — | +223.9% |
| Share buybacks | -$10.18M | $0 | $0 | — | — | — |
| Dividends paid | — | — | $0 | $0 | -$731.00K | — |
| Financing cash flow | $188.08M | -$267.60M | -$417.33M | $1.50B | — | +170.3% |
| Free cash flow | -$303.12M | -$21.17M | $562.18M | $158.42M | — | -1,331.8% |
| End cash position | $281.99M | $49.38M | $272.92M | $86.19M | — | +471.0% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $613.23M | $627.78M | $708.97M | $697.26M | $681.92M | -2.3% |
| Operating revenue | $565.55M | $627.78M | $708.97M | $697.26M | $609.62M | -9.9% |
| Cost of revenue | $349.83M | $349.75M | $385.71M | $375.07M | $357.31M | +0.0% |
| Gross profit | $263.41M | $278.03M | $323.26M | $322.20M | $324.60M | -5.3% |
| Selling, general & admin | $243.56M | $255.23M | $271.50M | $265.84M | $267.85M | -4.6% |
| Total operating expense | $243.56M | $255.23M | $271.50M | $265.84M | $267.85M | -4.6% |
| Operating income | $19.85M | $22.80M | $51.76M | $56.36M | $56.75M | -13.0% |
| Net interest income | -$34.54M | -$32.35M | -$27.93M | -$29.03M | -$26.01M | -6.8% |
| Pre-tax income | -$87.63M | -$16.25M | -$7.97M | -$3.63M | -$84.95M | -439.4% |
| Tax provision | $1.44M | -$9.78M | $1.47M | $1.97M | -$1.13M | +114.7% |
| Net income | -$89.07M | -$6.47M | -$56.33M | -$150.28M | -$869.06M | -1,277.1% |
| Net income to common | -$89.07M | -$6.47M | -$56.33M | -$150.28M | -$869.06M | -1,277.1% |
| Basic EPS | -1.16 | -0.08 | -0.73 | -1.94 | -11.30 | -1,350.0% |
| Diluted EPS | -1.16 | -0.08 | -0.73 | -1.94 | -11.30 | -1,350.0% |
| EBIT | -$53.09M | $16.10M | $19.96M | $25.39M | -$58.94M | -429.7% |
| EBITDA | $12.61M | $77.84M | $49.83M | $124.16M | -$15.95M | -83.8% |
| Basic shares | 76.69M | 76.43M | 76.70M | 77.29M | 76.94M | +0.3% |
| Diluted shares | 76.69M | 76.43M | 76.70M | 77.29M | 76.94M | +0.3% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Cash & equivalents | $7.65M | $336.88M | $281.99M | $32.84M | $38.26M | — | -97.7% |
| Cash & short-term investments | $7.65M | $336.88M | $281.99M | $32.84M | $38.26M | — | -97.7% |
| Accounts receivable | $120.08M | $103.70M | $95.91M | $169.73M | $162.38M | — | +15.8% |
| Inventory | $73.34M | $65.28M | $74.44M | $63.85M | $69.23M | — | +12.3% |
| Total current assets | $271.45M | $588.50M | $547.87M | $2.13B | $2.30B | — | -53.9% |
| Property, plant & equipment | $305.67M | $329.70M | $365.26M | $378.82M | $379.49M | — | -7.3% |
| Goodwill & intangibles | $1.31B | $1.34B | $1.36B | $1.39B | $1.42B | — | -2.2% |
| Total assets | $2.11B | $2.42B | $2.45B | $4.04B | $4.15B | — | -12.8% |
| Total current liabilities | $666.22M | $1.20B | $947.08M | $2.47B | $2.67B | — | -44.6% |
| Current debt | — | $581.25M | $250.00M | $280.00M | $383.00M | $47.50M | — |
| Long-term debt | $1.72B | $1.52B | $1.80B | $1.84B | $1.59B | — | +12.9% |
| Total debt | $1.78B | $2.17B | $2.12B | $2.20B | $2.06B | — | -17.9% |
| Total liabilities | $2.66B | $2.88B | $2.91B | $4.47B | $4.44B | — | -7.7% |
| Retained earnings | -$1.18B | -$1.09B | -$1.08B | -$1.02B | -$871.88M | — | -8.2% |
| Shareholder equity | -$550.94M | -$464.76M | -$460.98M | -$429.51M | -$281.01M | — | -18.5% |
| Working capital | -$394.77M | -$614.60M | -$399.20M | -$334.29M | -$376.01M | — | +35.8% |
| Net tangible assets | -$1.86B | -$1.80B | -$1.83B | -$1.82B | -$1.70B | — | -3.2% |
| Shares issued | 76.90M | 76.58M | 76.39M | 77.30M | 77.20M | — | +0.4% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Net income | -$89.07M | -$6.47M | $941.63M | -$956.68M | -$83.82M | -1,277.1% |
| Depreciation & amortisation | $65.70M | $61.74M | $29.87M | $98.76M | $42.99M | +6.4% |
| Stock-based compensation | $4.00M | $3.09M | -$4.46M | $8.04M | $4.87M | +29.6% |
| Change in working capital | $41.33M | -$59.05M | $209.50M | -$103.36M | -$37.42M | +170.0% |
| Operating cash flow | -$26.01M | -$50.08M | $68.19M | -$172.52M | $37.61M | +48.1% |
| Capital expenditure | -$48.65M | -$42.49M | -$9.29M | -$84.75M | -$59.17M | -14.5% |
| Investing cash flow | -$31.25M | $53.92M | $285.00M | -$39.46M | -$52.92M | -157.9% |
| Share buybacks | $0 | $0 | -$3.52M | $0 | -$5.15M | — |
| Financing cash flow | -$271.98M | $51.08M | -$117.50M | $181.10M | $31.70M | -632.4% |
| Free cash flow | -$74.65M | -$92.57M | $58.90M | -$257.27M | -$21.56M | +19.4% |
| End cash position | $7.65M | $336.88M | $281.99M | $46.17M | $77.09M | -97.7% |
Options analytics
Put / call volume
2.50
Put-heavy session
Put / call open interest
—
Positioning, not flow
Max pain
0.50
+7.3% from spot
ATM implied vol
25.0%
Nearest strike to spot
Skew (10% OTM)
-25.0%
Calls bid over puts
Call volume
2
Contracts, this expiry
Put volume
5
Contracts, this expiry
Heaviest call OI
0.50
0 contracts
Heaviest put OI
1.00
0 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -0.09 | -0.19 | -116.0% |
| Mar 2026 | -0.10 | -0.04 | +59.3% |
| Dec 2025 | 0.22 | 0.21 | -5.1% |
| Sep 2025 | 0.23 | 0.25 | +6.4% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -0.09 | 5 | $617.38M | -11.5% |
| Next quarter | 0.25 | 5 | $632.10M | -10.8% |
| Current year | -0.06 | 5 | $2.49B | -9.8% |
| Next year | 0.09 | 5 | $2.56B | +3.0% |
Analyst targets & ownership
Mean target$1.51
High target$1.75
Low target$1.30
Implied upside224.50%
Analyst count4
ConsensusHOLD
Strong buy / Buy0 / 0
Hold3
Sell / Strong sell0 / 2
Held by insiders7.68%
Held by institutions84.26%
Institutions holding203
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
0.60
-22.32% from price
SMA 20
0.81
-41.87% from price
SMA 50
1.38
-66.03% from price
SMA 100
2.25
-79.26% from price
SMA 200
2.44
-80.76% from price
EMA 12
0.64
-27.48% from price
EMA 26
0.90
-48.10% from price
EMA 50
1.34
-65.11% from price
RSI (14)
16.8
Oversold
MACD (12,26,9)
-0.26
Hist 0.00
ATR (14)
0.07
15.35% of price
Realised vol 30D
81.6%
Annualised
Bollinger upper
1.27
20, 2σ
Bollinger lower
0.35
20, 2σ
50 / 200 cross
Death
1.38 vs 2.44
Trend bias
Below 200
-80.76%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
0.88
Less volatile than market
Correlation to SPY
0.11
Largely independent
Realised vol 30D
81.6%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-91.8%
Peak to trough
Max drawdown 5Y
-99.1%
Peak to trough
ATR 14
0.07
15.35% of price
Beta (reported)
1.57
5Y monthly, from filing
Short interest
Shares short
8.90M
Prior 6.46M
Change vs prior
+37.8%
Shorts adding
% of float
14.28%
Elevated
% of shares out
11.57%
Against total outstanding
Days to cover
6.5
Crowded exit
Float
56.52M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 13, 26 | UBS | MAINTAINED | Neutral | Neutral |
| Aug 11, 26 | Citigroup | DOWNGRADE | Buy | Neutral |
| Jul 24, 26 | Citigroup | MAINTAINED | Buy | Buy |
| May 12, 26 | UBS | MAINTAINED | Neutral | Neutral |
| May 12, 26 | Citigroup | MAINTAINED | Buy | Buy |
| May 12, 26 | Baird | MAINTAINED | Outperform | Outperform |
| Feb 20, 26 | Leerink Partners | MAINTAINED | Market Perform | Market Perform |
| Jan 9, 26 | Citigroup | MAINTAINED | Buy | Buy |
| Nov 3, 25 | UBS | DOWNGRADE | Buy | Neutral |
| Aug 27, 25 | JP Morgan | MAINTAINED | Underweight | Underweight |
| Aug 13, 25 | UBS | MAINTAINED | Buy | Buy |
| Aug 12, 25 | Baird | MAINTAINED | Outperform | Outperform |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield0.04%
Payout ratio0.00%
Ex-dividend dateDec 14, 2021
Next pay dateDec 31, 2021
Last split3:2
Split dateApr 1, 2010
SEC filings
Corporate Changes & Voting Matters
8-K/A · 2026-09-28
Corporate Changes & Voting Matters
8-K · 2026-09-17
Corporate Changes & Voting Matters
8-K · 2026-08-17
Trading Registrations
8-A12B · 2026-08-10
Offering Registrations
S-3 · 2026-07-15
Corporate Changes & Voting Matters
8-K · 2026-06-25
Corporate Changes & Voting Matters
8-K · 2026-06-15
Specialized Disclosure Report filed pursuant to Section 1502 of the Dodd-Frank Wall Street Reform and Consumer Protection Act relating to the use of conflict minerals (Rule 13p-1)
SD · 2026-05-29
Headlines
New Strong Sell Stocks for October 6th
Zacks · 1d ago
Accendra Health Names Kenneth Gardner-Smith as President and Chief Executive Officer to Lead the Company’s Next Chapter of Growth
Business Wire · 20d ago
Accendra Health drops equity issuance plan as CEO succession process advances
InvestorsHub · 51d ago
Accendra Health Updates on Capital Allocation and CEO Succession Timing Plans
Business Wire · 51d ago
UBS Adjusts Price Target on Acadia Healthcare to $1.50 From $4.50, Keeps Neutral Rating
MT Newswires · 54d ago
UBS Adjusts Price Target on Accendra Health to $1.50 From $4.50, Keeps Neutral Rating
MT Newswires · 55d ago
Accendra Health Announces Adoption of Tax Asset Preservation Plan To Protect Long Term Shareholder Value
Business Wire · 58d ago
Accendra Health Chief Executive Edward Pesicka to Retire
MT Newswires · 58d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.